
WHAT IS CLAIMED IS:

1. A pharmaceutical combination comprising:

(1) a compound of formula (I) formulated for storage at room temperature




(I);

(2) at least one additional therapeutic agent;

and optionally one or more pharmaceutically acceptable carriers.

2. The pharmaceutical combination of Claim 1, wherein the compound of formula (I) is formulated in a stabilizing formulation that allows the compound to be stored at room temperature for at least six months.

3. The pharmaceutical combination of Claim 2, wherein the at least one additional therapeutic agent is a compound of formula (II):




(II).

4. The pharmaceutical combination of Claim 3, wherein the compound of formula (I) and the compound of formula (II) are formulated in a fixed dose tablet or capsule that contains 1-15 mg of the compound of formula (I) and 25-250 mg of the compound of formula (II).

5. The pharmaceutical combination of Claim 4, wherein the fixed dose tablet or capsule contains 2.5 mg or 5 mg of the compound of formula (I) and 50 mg or 75 mg of the compound of formula (II).

6. The pharmaceutical combination of Claim 4, wherein the fixed dose tablet contains 5 mg of the compound of formula (I) and 75 mg of the compound of formula (II).

7. The pharmaceutical combination of Claim 2, wherein the at least one additional therapeutic agent is a compound of formula (III) or its pharmaceutically acceptable salts:



(III).

8. The pharmaceutical combination of Claim 7, wherein the compound of formula (I) and the compound of formula (III) are formulated in a fixed dose tablet or capsule that contains 1-15 mg of the compound of formula (I) and 5-100 mg of the sodium salt of the compound of formula (III).

9. The pharmaceutical combination of Claim 8, wherein the fixed dose tablet or capsule contains 2.5 mg or 5 mg of the compound of formula (I), and 10 mg, 20 mg or 30 mg of the sodium salt of compound of formula (III).

10. The pharmaceutical combination of Claim 1, wherein the at least one additional therapeutic agent is a PPAR agonist.

11. The pharmaceutical combination of Claim 7, wherein the PPAR agonist is lanifibranor.

12. The pharmaceutical combination of Claim 1, formulated for simultaneous, separate or sequential use in the treatment of non-alcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).


13. The pharmaceutical combination of Claim 1, formulated in an injectable suspension, a gel, an oil, a pill, a tablet, a suppository, a powder, a capsule, an aerosol, an ointment, a cream, a patch, or means of galenic forms for a prolonged and/or slow release.

14. Use of the pharmaceutical combination of claim 1 in preparing a producet for treating disease in a patient in need thereof, comprising:

administering to the patient an effective amount of.

15. The use of Claim 14, wherein the compound of formula (I) is formulated in a stabilizing formulation that allows the compound to be stored at room temperature for at least six months.

16. The use of Claim 14, wherein the at least one additional therapeutic agent is a compound of formula (II):



(II).

17. The use of Claim 16, wherein the pharmaceutical combination is formulated as a fixed dose tablet or capsule that contains 1-15 mg of the compound of formula (I) and 25-250 mg of the compound of formula (II).

18. The use of Claim 17, wherein the fixed dose tablet or capsule contains 2.5 mg or 5 mg of the compound of formula (I) and 50 mg of the compound of formula (II).

19. The use of Claim 17, wherein the fixed dose tablet or capsule contains 2.5 mg or 5 mg of the compound of formula (I) and 75 mg of the compound of formula (II).

20. The use of Claim 14, wherein the disease is selected from the group consisting of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).